NXEN (Nexien BioPharma) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2025)


What is Nexien BioPharma LT-Debt-to-Total-Asset?

Nexien BioPharma NXEN LT-Debt-to-Total-Asset is 0.00 as of Mar. 2025.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nexien BioPharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2025 was 0.00.

Nexien BioPharma's long-term debt to total assets ratio stayed the same from Mar. 2024 (0.00) to Mar. 2025 (0.00).

Nexien BioPharma  (OTCPK:NXEN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nexien BioPharma LT-Debt-to-Total-Asset Related Terms

Nexien BioPharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Nexien BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexien BioPharma LT-Debt-to-Total-Asset Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nexien BioPharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nexien BioPharma LT-Debt-to-Total-Asset Calculation

Nexien BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )/Total Assets (A: Jun. 2024 )
=0/0.004
=

Nexien BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (Q: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )/Total Assets (Q: Mar. 2025 )
=0/0.008
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Nexien BioPharma (NXEN) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Nexien BioPharma and its competitors.
Is Nexien BioPharma's LT-Debt-to-Total-Asset too high?
Nexien BioPharma's current LT-Debt-to-Total-Asset is 0.00.
How does Nexien BioPharma's LT-Debt-to-Total-Asset compare to FLHLF and ZTS?
Nexien BioPharma's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Nexien BioPharma and its competitors. Nexien BioPharma's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexien BioPharma stock overvalued right now?
Nexien BioPharma (NXEN) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Nexien BioPharma (NXEN), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexien BioPharma Business Description

Address 4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is engaged in pre-clinical and drug development activities, by U.S. Food and Drug Administration (FDA) protocols, for certain pharmaceutical formulations that include cannabinoids. The company is pursuing the formulation and development of drugs containing cannabinoids for the treatment of various diseases, disorders, and medical conditions.